[CAS NO. 83461-56-7] Mifamurtide

Name: Mifamurtide
Brand: Arctom Scientific
SKU: AS907818

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [83461-56-7]

Distributor

Catalog

AS907818

Brand

Arctom Scientific

CAS

83461-56-7

DESCRIPTION [83461-56-7]

Overview

MDL	-
Molecular Weight	1237.50
Molecular Formula	C59H109N6O19P
SMILES	CCCCCCCCCCCCCCCC(OC[C@@H](OC(CCCCCCCCCCCCCCC)=O)COP(OCCNC([C@@H](NC(CC[C@@H](NC([C@@H](NC([C@H](O[C@]([C@H](O)[C@H](O)CO)([H])[C@@H](NC(C)=O)C=O)C)=O)C)=O)C(N)=O)=O)C)=O)(O)=O)=O

For research use only. We do not sell to patients.

Summary

Mifamurtide (MTP-PE), an analog of the muramyl dipeptide (MDP), is a nonspecific immunomodulator by stimulating the immune response activating macrophages and monocytes. Mifamurtide, an orphan drug, is a specific ligand of NOD2 used as an insulin sensitizer. Mifamurtide has the potential for osteosarcoma research ^[1] ^[2] ^[3] .

IC50 & Target

NOD2

In Vitro

Mifamurtide (MTP-PE; 100 µM) induces a reduction of MG63 cells number when co-cultured with macrophages ^[3] .
Mifamurtide (100 µM) increases both the M1 polarization marker iNOS and the M2 polarization marker CD206 mRNAs; both pro-inflammatory (IL-1β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines. Mifamurtide increases the iron transporter DMT1 protein ^[3] .
L-mifamurtide (5, 5000 nM; for 48 hours) alone has no direct effect on the proliferation rate of the two osteosarcoma cell lines MOS-J and KHOS in vitro or in vivo ^[1] .
Mifamurtide acts as a nonspecific immunomodulator by activating macrophages and monocytes related to the upregulation of tumoricidal activity and secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6, IL-8, IL-12, nitric oxide (NO), prostaglandin E2 (PGE2) and PGD2 ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mifamurtide (MTP-PE; 1 mg/kg; i.v.; twice per week for 4 weeks) causes a trend of diminished spontaneous lung metastasis dissemination ^[1] .
Mifamurtide (50 μg/mouse) improves glucose tolerance during endotoxemia in mice. Mifamurtide (equivalent to 20 μg MDP; 4 times per week for 5 weeks) improves glucose tolerance in HFD-fed mice without altering body mass ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, BALB/c mice with KHOS osteosarcoma cells ^[1]
Dosage:	1 mg/kg
Administration:	IV; twice per week for 4 weeks
Result:	Caused a trend of diminished spontaneous lung metastasis dissemination in xenogeneic (KHOS) and syngeneic (MOS-J) models.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03643133	UNICANCER	Osteosarcoma	October 23, 2018	Phase 2
NCT02441309	University of Oxford\|Millennium: The Takeda Oncology Company\|National Institute for Health Research, United Kingdom\|Oxford University Hospitals NHS Trust\|European Commission	Osteosarcoma	October 2014	Phase 2
NCT00631631	Millennium Pharmaceuticals, Inc.	Osteosarcoma	January 2008
NCT01459484	Italian Sarcoma Group	Osteosarcoma	June 23, 2011	Phase 2
NCT01194284	Millennium Pharmaceuticals, Inc.\|Takeda	Osteosarcoma	December 2011
NCT04571229	Memorial Sloan Kettering Cancer Center	Osteosarcoma

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 80.81 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8081 mL	4.0404 mL	8.0808 mL
5 mM	0.1616 mL	0.8081 mL	1.6162 mL
10 mM	0.0808 mL	0.4040 mL	0.8081 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (2.02 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-α-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-

L-Alaninamide, N-(N-acetylmuramoyl)-L-alanyl-D-α-glutaminyl-N-[4-hydroxy-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-, P-oxide, (R)-

N-(N-Acetylmuramoyl)-L-alanyl-D-α-glutaminyl-N-[(7R)-4-hydroxy-4-oxido-10-oxo-7-[(1-oxohexadecyl)oxy]-3,5,9-trioxa-4-phosphapentacos-1-yl]-L-alaninamide

CGP 19835

Muramoyl tripeptide phosphatidylethanolamine

MTP-PE

MLV 19835

Mifamurtide

L-MTP-PE